One hundred ninety-four patients with cryptococcal meningitis were enrolled in a multicenter, prospective, randomized clinical trial to compare the efficacy and toxicity of four as compared with six weeks of combination amphotericin B and flucytosine therapy. Among 91 patients who met preestablished criteria for randomization, cure or improvement was noted in 75 percent of those treated for four weeks and in 85 percent of those treated for six weeks. The estimated relapse rate for the four-week regimen was higher--27 as compared with 16 percent--whereas the incidence of toxic effects for the two regimens was similar--44 as compared with 43 percent. Among 23 transplant recipients, 4 of 5 treated for four weeks relapsed, leading to the decision to treat the rest of the group for six weeks. Only 3 of the 18 treated for six weeks relapsed. In a third group of 80 patients, the protocol was not followed during the initial four weeks, and these patients were not randomized. Thirty-eight died or relapsed. Multifactorial analysis of pretreatment factors for all 194 patients identified three significant predictors (P less than 0.05) of a favorable response: headache as a symptom, normal mental status, and a cerebrospinal fluid white-cell count above 20 per cubic millimeter. These and other findings in this study are consistent with the view that the four-week regimen should be reserved for patients who have meningitis without neurologic complications, underlying disease, or immunosuppressive therapy; a pretreatment cerebrospinal fluid white-cell count above 20 per cubic millimeter and a serum cryptococcal antigen titer below 1:32; and at four weeks of therapy, a negative cerebrospinal fluid India ink preparation and serum and cerebrospinal fluid cryptococcal-antigen titers below 1:8. Patients who do not meet these criteria should receive at least six weeks of therapy.
This article has been cited by other articles:
Andes, D., Pascual, A., Marchetti, O.
(2009). Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications. Antimicrob. Agents Chemother.
53: 24-34
[Full Text]
Lui, G., Lee, N., Ip, M., Choi, K.W., Tso, Y.K., Lam, E., Chau, S., Lai, R., Cockram, C.S.
(2006). Cryptococcosis in apparently immunocompetent patients. QJM
99: 143-151
[Abstract][Full Text]
Duffalo, M. L.
(2006). Fungal Opportunistic Infections in HIV Disease. Journal of Pharmacy Practice
19: 17-30
[Abstract]
Bicanic, T., Harrison, T. S.
(2005). Cryptococcal meningitis. Br Med Bull
72: 99-118
[Abstract][Full Text]
Fries, B. C., Lee, S. C., Kennan, R., Zhao, W., Casadevall, A., Goldman, D. L.
(2005). Phenotypic Switching of Cryptococcus neoformans Can Produce Variants That Elicit Increased Intracranial Pressure in a Rat Model of Cryptococcal Meningoencephalitis. Infect. Immun.
73: 1779-1787
[Abstract][Full Text]
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A.
(2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev.
18: 163-194
[Abstract][Full Text]
Miller, J. L., Schell, W. A., Wills, E. A., Toffaletti, D. L., Boyce, M., Benjamin, D. K. Jr., Bartroli, J., Perfect, J. R.
(2004). In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans. Antimicrob. Agents Chemother.
48: 384-387
[Abstract][Full Text]
Purdy, B. D.
(2000). Management and Prevention of Opportunistic Infections in the HIV-Infected Patient. Journal of Pharmacy Practice
13: 475-498
[Abstract]
Vermes, A., Guchelaar, H.-J., Dankert, J.
(2000). Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother
46: 171-179
[Abstract][Full Text]
Schell, W. A., De Almeida, G. M. D., Dodge, R. K., Okonogi, K., Perfect, J. R.
(1998). In Vitro and In Vivo Efficacy of the Triazole TAK-187 against Cryptococcus neoformans. Antimicrob. Agents Chemother.
42: 2630-2632
[Abstract][Full Text]
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., Powderly, W. G., Dismukes, W. E., The National Institute of Allergy and Infectious D,
(1997). Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome. NEJM
337: 15-21
[Abstract][Full Text]
Como, J. A., Dismukes, W. E.
(1994). Oral Azole Drugs as Systemic Antifungal Therapy. NEJM
330: 263-272
[Full Text]
King, C., Finley, R., Chapman, S. W.
(1990). Prostatic Cryptococcal Infection. ANN INTERN MED
113: 720-720
[Abstract]
Galgiani, J. N.
(1990). Fluconazole, a New Antifungal Agent. ANN INTERN MED
113: 177-179
[Abstract]
Larsen, R. A., Leal, M. A. E., Chan, L. S.
(1990). Fluconazole Compared with Amphotericin B plus Flucytosine for Cryptococcal Meningitis in AIDS: A Randomized Trial. ANN INTERN MED
113: 183-187
[Abstract]
Denning, D. W., Tucker, R. M., Hanson, L. H., Hamilton, J. R., Stevens, D. A.
(1989). Itraconazole Therapy for Cryptococcal Meningitis and Cryptococcosis. Arch Intern Med
149: 2301-2308
[Abstract]
Larsen, R. A., Bozzette, S., McCutchan, J. A., Chiu, J., Leal, M. A., Richman, D. D., California Collaborative Treatment Group,
(1989). Persistent Cryptococcus neoformans Infection of the Prostate after Successful Treatment of Meningitis. ANN INTERN MED
111: 125-128
[Abstract]
Esposito, R., Foppa, C. U., Antinori, S.
(1989). Fluconazole for Cryptococcal Meningitis. ANN INTERN MED
110: 170-170
[Abstract]
Zuger, A., Schuster, M., Simberkoff, M. S., Rahal, J. J., Holzman, R. S.
(1988). Maintenance Amphotericin B for Cryptococcal Meningitis in the Acquired Immunodeficiency Syndrome (AIDS). ANN INTERN MED
109: 592-593
[Abstract]
Previous
